A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Inclusion Criteria:

- KRAS and NRAS wild type metastatic colorectal cancer

- Progression following treatment for colorectal cancer with irinotecan, oxaliplatin and
fluoropyrimidine therapy in the metastatic setting.

- Eastern Cooperative Oncology Group [ECOG] Performance Status of 0, 1, or 2

- At least one measurable lesion by Response Evaluation Criterion in Solid Tumors
[RECIST]

Exclusion Criteria:

- More than 2 prior cytotoxic chemotherapy regimens for metastatic colorectal cancer.

- Prior treatment with a PI3K, mTOR, AKT or EGFR inhibitor

- Patients who have discontinued treatment with prior irinotecan therapy due to
toxicity.

- Prior radiation to the pelvis or abdomen

- Patients with history of interstitial lung disease.